SynAct Pharma has received encouraging results from the clinical trial which the company launched in April earlier this year.
In the trial, patients who had received SynAct Pharma's anti-inflammatory treatment going by the name of AP1189, showed significant effect compared with those given placebo treatment.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.